TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05993325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19-1 OMI
Description: 3000 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular administration in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)
Description: 1000 participants will receive investigational product (Comirnaty Bivalent) via intramuscular administration in the deltoid muscle
Study: NCT05708222

Intervention type: DEVICE
Intervention: MEB-001
Description: The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.

Intervention type: DEVICE
Intervention: MEB-001
Description: The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.
Study: NCT06636591

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin
Description: Drugs was given a few days after multimodal thermal therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin
Description: Drugs was given a few days after multimodal thermal therapy
Study: NCT05369156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Care
Description: The actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent and the duration of the thrust is always less than 200 milliseconds.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
Study: NCT05829317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Intravenous Magnesium sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study: NCT05145894

Intervention type: DEVICE
Intervention: Lung auscultation with LungPass device (electronic auscultation)
Description: Lung auscultation with electronic stethoscope

Intervention type: DEVICE
Intervention: Lung auscultation with LungPass device (electronic auscultation)
Description: Lung auscultation with electronic stethoscope
Study: NCT05540275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
Study: NCT04389671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant
Description: Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
Study: NCT06401109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AquaPass
Description: The AquaPass system works by activating the body's natural sweating mechanism to remove excess fluid from the interstitial compartment. This process is achieved by wearing a garment that creates optimal microclimate conditions around the skin.~The system is controlled by a portable unit that delivers warm air to the wearable component while ensuring patient safety.
Study: NCT06466772

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hyper-personalized feedback (HPF intervention)
Description: For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hyper-personalized feedback (HPF intervention)
Description: For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted auditory stimulation during sleep (TASS verum intervention)
Description: The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control targeted auditory stimulation during sleep (TASS sham intervention)
Description: Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
Study: NCT05343650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVAPAK nasal packing applied to forearm
Description: Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVAPAK nasal packing applied to nasal cavity
Description: A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
Study: NCT05366647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: canaloplasty
Description: canaloplasty ab interno with tensioning suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gonioscopy-assisted Transluminal Trabeculotomy
Description: Gonioscopy-assisted Transluminal Trabeculotomy ab interno
Study: NCT05253807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: 13.5 mg tablet
Study: NCT05694208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Group
Description: In the first pre-operative interview at the gynecological oncology outpatient clinic of the relevant hospital, the purpose of the research will be explained to the patients and an informed consent form will be filled. The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
Study: NCT06288711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Description: Twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by therapists trained in prolonged exposure therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Description: Twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by therapists trained in prolonged exposure therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Financial incentives contingent upon completion of prolonged exposure therapy sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.
Study: NCT04761588

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tyr sphere
Description: Tyr sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP) and docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content.
Study: NCT05317455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate
Description: Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dichloroacetate
Description: Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
Study: NCT06567873

Intervention type: OTHER
Intervention: Gastric Ultrasound Exam
Description: A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
Study: NCT04149457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Thirty minutes of training on computerized, casual video games.
Study: NCT05233917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil use
Description: Olive oil, 25-30g/d by day for 6 month

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MLCT oil use
Description: MLCT oil, 25-30g/d by day for 6 month
Study: NCT06081114

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Supplement
Description: A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Supplement
Description: A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Supplement
Description: A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Micronutrient Supplement
Description: A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.
Study: NCT05688709

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WhatsApp peer support group
Description: YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp peer support group
Description: YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.
Study: NCT05524532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immulina TM
Description: Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inert form of cellulose acetate.
Study: NCT05970406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity dysphagia therapy
Description: Intensive swallowing interventions with Speech Language Pathologists to begin within 24 hours of video swallow study results. Daily treatment will include two 30-minute sessions, 5-6 days a week which will include the evidence-based dysphagia exercises focusing on tongue resistance, head lift/chin tuck against resistance and expiratory muscle strength training tasks
Study: NCT04867070

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NAS score
Description: Participants will be recorded according to the NAS and W-BAS pain scores
Study: NCT05089175

Intervention type: DRUG
Intervention: Low-dose aspirin
Description: FIGO adopts and supports that in high-risk women, defined by the first-trimester combined test, aspirin \~150 mg/night should be commenced at 11-14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when pre-eclampsia is diagnosed.
Study: NCT05171725

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG,PSG
Description: concurrent overnight sleep study with full electroencephalography (in-lab or at home)

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG,PSG
Description: concurrent overnight sleep study with full electroencephalography (in-lab or at home)

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG,PSG
Description: concurrent overnight sleep study with full electroencephalography (in-lab or at home)

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG,PSG
Description: concurrent overnight sleep study with full electroencephalography (in-lab or at home)

Intervention type: DIAGNOSTIC_TEST
Intervention: biosample collection (blood and CSF)
Description: blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information

Intervention type: DIAGNOSTIC_TEST
Intervention: biosample collection (blood and CSF)
Description: blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information

Intervention type: DIAGNOSTIC_TEST
Intervention: biosample collection (blood and CSF)
Description: blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
Study: NCT06128967

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvoxamine Maleate 100 MG
Description: Fluvoxamine Maleate 100 mg each pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo talc pills of same shape, color, weight if compared with active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo talc pills of same shape, color, weight if compared with active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin Extended Release Oral Tablet
Description: Metformin Extended release oral tablets of 750 mg each pill
Study: NCT06059625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rotatori cuff repair
Description: rotatori cuff repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rotatori cuff repair
Description: rotatori cuff repair
Study: NCT06152796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Anti_inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Non steroidal anti_inflammatory drug
Study: NCT05316454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-efficacy support
Description: self-efficacy support
Study: NCT03741777

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear oral fluid
Description: clear oral fluid including water, pulp-free juice and tea or coffee without milk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear oral fluid
Description: clear oral fluid including water, pulp-free juice and tea or coffee without milk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear oral fluid
Description: clear oral fluid including water, pulp-free juice and tea or coffee without milk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear oral fluid
Description: clear oral fluid including water, pulp-free juice and tea or coffee without milk.
Study: NCT06627257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose
Description: 2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose
Description: 10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
Study: NCT06628063

Intervention type: OTHER
Intervention: ultrasound evaluation
Description: Ultrasound scan of fetus in second and third trimestrers

Intervention type: OTHER
Intervention: ultrasound evaluation
Description: Ultrasound scan of fetus in second and third trimestrers
Study: NCT05302128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold vapor
Description: Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th,12th, and 24th hours after the cold vapor application in the postoperative service.
Study: NCT06627777

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Laboratory tasks in early adolescence
Description: Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
Study: NCT05171725

Intervention type: DIAGNOSTIC_TEST
Intervention: biosample collection (blood and CSF)
Description: blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological testing
Description: paper and pencil, as well as tablet based cognitive testing

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological testing
Description: paper and pencil, as well as tablet based cognitive testing

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological testing
Description: paper and pencil, as well as tablet based cognitive testing

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological testing
Description: paper and pencil, as well as tablet based cognitive testing

Intervention type: DIAGNOSTIC_TEST
Intervention: actigraphy
Description: week long actigraphy assessment with concurrent sleep diary acquisition
Study: NCT05287100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is \< 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to \< 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (\>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is \< 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to \< 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (\>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3